ITM has met primary endpoints in its Phase 3 COMPETE trial for gastroenteropancreatic neuroendocrine tumors and plans to submit a New Drug Application to the U.S. FDA in 2025.
Founders
Dr. Andrew Cavey
Company Description
ITM Isotope Technologies Munich SE is a radiopharmaceutical biotech firm focused on developing precision oncology treatments, particularly for hard-to-treat neuroendocrine tumors. The company is advancing its lead candidate, ITM-11, through late-stage clinical trials and aims to establish a global supply of non-carrier-added Lutetium-177.